Systemic Amyloidosis Therapeutic Market Forecast 2026–2030 Presenting Long-Term Industry Insights

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Systemic Amyloidosis Therapeutic Market Expected To Change From 2026 To 2030?

The systemic amyloidosis therapeutic market has experienced robust expansion recently. Projections indicate its expansion from $5.67 billion in 2025 to $6.2 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. Several factors contributed to this historic growth, including the past underdiagnosis of amyloidosis, a dependence on chemotherapy treatments, the rise in hematology treatment centers, heightened awareness of rare diseases, and the initial uptake of proteasome inhibitors.

The systemic amyloidosis therapeutic market is projected to experience substantial expansion over the coming years. This market is forecast to reach $8.88 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this growth during the forecast period include an increase in rare disease diagnosis rates, the proliferation of targeted biologic medications, a rise in gene silencing therapy approvals, the expansion of specialized clinic networks, and more robust orphan drug incentives. Key trends anticipated during this period encompass the development of targeted amyloid protein stabilizer drugs, gene silencing amyloidosis therapies, treatments based on monoclonal antibodies, combination regimen treatment protocols, and organ-specific supportive drug strategies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33337&type=smp

Which Key Factors Are Driving The Systemic Amyloidosis Therapeutic Market Growth?

The expansion in the use of personalized medicine strategies is anticipated to boost the growth of the systemic amyloidosis therapeutic market in the future. This medical method involves tailoring treatment and prevention plans to an individual’s genetic makeup, biomarkers, and specific disease traits. The increasing need for personalized medicine stems from advancements in genomic and biomarker technologies, which enable medical professionals to accurately pinpoint disease causes and customize therapies, thereby enhancing effectiveness and minimizing side effects for individual patients. The integration of personalized medicine elevates the demand for systemic amyloidosis therapeutics because individuals suffering from systemic amyloidosis exhibit distinct amyloid subtypes (e.g., AL, ATTR) and genetic variations. Consequently, successful treatment necessitates therapies precisely engineered to address the patient’s particular disease profile, guaranteeing optimal efficacy and reduced adverse reactions. For instance, in April 2025, as reported by the Personalized Medicine Coalition (PMC), a US-based based nonprofit advocacy and educational organization, the FDA sanctioned 16 new personalized treatments for rare disease patients in 2023, marking an increase from six in 2022. Thus, the increasing embrace of personalized medicine approaches is fueling the expansion of the systemic amyloidosis therapeutic market.

How Is The Systemic Amyloidosis Therapeutic Market Organized By Segment Classification?

The systemic amyloidosis therapeutic market covered in this report is segmented –

1) By Product Type: Small Molecule Drugs; Biologic Therapies; Monoclonal Antibodies; Chemotherapy Based Regimens; Targeted Therapies; Supportive Treatments

2) By Formulation: Tablets; Capsules; Injection

3) By Route of Administration: Oral; Intravenous; Subcutaneous

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

5) By End User: Hospitals; Specialty Clinics; Specialty Pharmacies; Research and Academic Institutes; Other End Users

Subsegments:

1) By Small Molecule Drugs: Proteasome Inhibitors; Stabilizers of Transthyretin Protein; Amyloid Fibril Disruptors; Immunomodulatory Small Molecules

2) By Biologic Therapies: Recombinant Protein Therapies; Gene Silencing Biologic Agents; Plasma Derived Biologic Products

3) By Monoclonal Antibodies: Anti Amyloid Fibril Antibodies; Anti Light Chain Antibodies; Targeted Clearance Antibodies

4) By Chemotherapy Based Regimens: Alkylating Agent Based Regimens; Proteasome Inhibitor Based Chemotherapy; Combination Chemotherapy Protocols

5) By Targeted Therapies: Targeted Light Chain Suppression Therapies; Targeted Transthyretin Reduction Therapies; Organ Specific Targeted Treatments

6) By Supportive Treatments: Cardiac Supportive Therapies; Renal Supportive Therapies; Neurological Symptom Management Therapies; Nutritional and Palliative Care Therapies

Which Trends Are Influencing Demand In The Systemic Amyloidosis Therapeutic Market?

Leading companies in the systemic amyloidosis therapeutic market are increasingly concentrating on developing advanced, targeted treatment strategies, particularly RNA interference-based therapies. These approaches aim to tackle the fundamental genetic factors contributing to protein misfolding conditions, slow down disease progression, and enhance long-term health outcomes for patients. RNA interference-based therapies function by specifically deactivating genes that cause disease, thereby diminishing the creation of detrimental proteins responsible for systemic organ damage. As an illustration, in March 2025, Alnylam Pharmaceuticals, a biotechnology firm based in the US, introduced AMVUTTRA. AMVUTTRA provides a focused, disease-modifying therapy for adults experiencing transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This therapeutic, developed by Alnylam Pharmaceuticals, marks the first RNAi treatment proven to lessen cardiovascular fatalities, hospital admissions, and urgent heart failure incidents in this patient demographic. AMVUTTRA operates by swiftly inhibiting transthyretin production at its origin, addressing the root cause of amyloid accumulation. It exhibits steady positive effects on cardiovascular health indicators, physical capability, and overall quality of life.

Who Are The Industry Participants Involved In The Systemic Amyloidosis Therapeutic Market?

Major companies operating in the systemic amyloidosis therapeutic market are Johnson & Johnson Services Inc., Sanofi SA, Novartis Plc, AstraZeneca Plc, GSK Plc, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals, Arcturus Therapeutics Inc, Prothena Biosciences, Fortress Biotech Inc., Intellia Therapeutics Inc., Zentalis Pharmaceuticals Inc., BridgeBio Pharma Inc., Neurimmune AG, HaemaLogix Pty Ltd., Attralus Inc., and Oncopeptides AB.

Get The Full Systemic Amyloidosis Therapeutic Market Report:

https://www.thebusinessresearchcompany.com/report/systemic-amyloidosis-therapeutic-market-report

Where Is The Systemic Amyloidosis Therapeutic Market Most Concentrated Geographically?

North America was the largest region in the systemic amyloidosis therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic amyloidosis therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Systemic Amyloidosis Therapeutic Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=33337&type=smp

Browse Through More Reports Similar to the Global Systemic Amyloidosis Therapeutic Market 2026, By The Business Research Company

Transthyretin Amyloidosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Atrophic Glossitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/atrophic-glossitis-treatment-global-market-report

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795